Kosaka T

No ORCID on file · 1 paper in corpus

case-report 2022

Case report: Posterior reversible encephalopathy syndrome, an adverse effect of lenvatinib and pembrolizumab combination therapy, in a patient with advanced endometrial cancer

Frontiers in oncology ·doi:10.3389/fonc.2022.1079716

BACKGROUND: Lenvatinib-pembrolizumab combination (LEAP) is an approved therapy in Japan for advanced endometrial cancer, based on the data from the KEYNOTE-775 clinical trial. We report a case of posterior reversible encephalopathy syndrome…